How Apyx Medical Was Crushed by the FDA

By Chris Lange Updated Jan 6, 5:47AM EST · Published Apr 2, 10:45AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

How Apyx Medical Was Crushed by the FDA — © evgenyatamanenko / Getty Images

Apyx Medical Corp. (NASDAQ: APYX) shares dropped sharply on Tuesday after the company announced that it has voluntarily withdrawn its application for premarket notification 510(k) regulatory clearance of J-Plasma/Renuvion for use in dermal resurfacing procedures.

However, the firm noted that it will continue to work with the U.S. Food and Drug Administration (FDA) relative to the development of a new 510(k) submission. Currently, Apyx cannot provide a timeline for resubmission, but it intends to do so after further discussions with the FDA.

Apyx originally filed to market and sell Renuvion Cosmetic Technology for dermal resurfacing procedures.

In the course of its review of Apyx’s submission, the FDA raised a number of questions and concerns related to superior clinical results from one investigational center as compared to the other two investigational centers in the study. The FDA also questioned the potential impact of protocol deviations at this investigational center, including the prophylactic use of methylprednisolone in all but five subjects treated.

[nativounit]

Shawn Roman, vice president of research and development for Apyx Medical, commented:

The IDE study results show good progress towards being able to eventually demonstrate the efficacy of our Renuvion Cosmetic Technology as more than 90% of subjects in the study experienced an improvement in appearance as assessed by investigators, and the independent photographic reviewers were able to correctly identify post treatment photographs in more than 97% of subjects. Unfortunately, we experienced a larger than expected range of clinical outcomes in the study due primarily to the inconsistent application of treatment time on tissue among investigators at the three centers.

Shares of Apyx were last seen down over 44% at $3.86, in a new 52-week range of $3.84 to $8.89. The consensus price target is $11.00.

[recirclink id=538528]

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.